Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Portuguese researchers lead international consortium to develop novel clinical drug

30.10.2008
IMM leads first Portuguese coordination of FP-7 Marie-Curie Action IAPP (Industry-Academia Partnerships and Pathways) in partnership with the biotech company BIOALVO.

A five-partner European consortium coordinated by Portuguese researchers from the Instituto de Medicina Molecular (IMM) in Lisbon will perform the industrial development of a novel pharmaceutical drug. This novel drug has analgesic properties and has potential therapeutic application in the fight against neurodegenerative diseases such as Alzheimer’s or Parkinson’s diseases.

The compound (BLV200704) was conceived by Miguel Castanho’s research team, who is an IMM researcher, and was then licensed to the biotech company BIOALVO, which collaborated in subsequent stages of development of the drug.

The first steps of the research that lead to the development of BLV200704 resulted from collaboration between Miguel Castanho’s and Isaura Tavares’ research teams (IMM and Faculdade de Medicina/IBMC, Oporto University, Portugal, respectively) and counted on BIOALVO partnership in a latter stage of development.

The industrial development of the drug by a consortium of the Portuguese teams – IMM and BIOALVO - and two other from Spain and Germany is now approved by Marie-Curie IAPP Action (Industry-Academia Partnerships and Pathways – IAPP **), will involve approximately 600.000,00 Euros and is coordinated by Miguel Castanho at IMM, Lisbon.

The project, called PEP2BRAIN, will consolidate the pharmacological development of BLV200704 and its potential derivatives.

This is the first Portuguese partnership successfully approved by the demanding and highly competitive IAPP Marie-Curie Action from the European Seventh Framework Programme (FP-7). Marie-Curie Actions from the FP-7 “People” Programme, and in particular IAPP, seek the support of innovative partnerships between public research centers and private institutions, namely small and medium enterprises, which have the ultimate goal of developing novel products and solutions.

“The EU approval of this project shows the emergence of an economy of innovation in Portugal and reflects the growth of scientific knowledge and a novel attitude of Portuguese researchers”, says Miguel Castanho, researcher at IMM and coordinator of the present consortium. “In our specific case, the partnership with industry, namely with BIOALVO, has been highly productive and reveals the potential to develop novel products capable of contributing to the enhancement of the life standards, especially of those who suffer from disease. This potential has been recognized by the panel of experts that recommended the approval of our application to EU’s IAPP Action.”

Patrícia Calado, BIOALVO’s Drug Discovery and Development Director, said: “It is very rewarding for BIOALVO to be the first Portuguese company to successfully accomplish the evaluation step of an FP7 IAPP proposal. The achievement of this milestone reinforces the value of establishing high quality partnerships between industry and academia. The work developed in collaboration with the group of Prof. Miguel Castanho is a combined effort acknowledged by the European Commission as a high-quality translational research program which is now successfully moving into advanced phases of drug development”.

* Members of the consortium: Instituto de Medicina Molecular (Portugal), BIOALVO SA (Portugal), University of Girona (Spain), Synovo GmbH (Germany) and University Eberhard Karls, Tübingen (Germany).

Marta Agostinho | alfa
Further information:
http://cordis.europa.eu/fp7/people/industry-academia_en.html
http://www.imm.ul.pt

Further reports about: Alzheimer BIOALVO CONSORTIUM Development Drug FP-7 IAPP IMM Lead Marie-Curie Molecular Parkinson develop neurodegenerative disease novel

More articles from Life Sciences:

nachricht Magic number colloidal clusters
13.12.2018 | Friedrich-Alexander-Universität Erlangen-Nürnberg

nachricht Record levels of mercury released by thawing permafrost in Canadian Arctic
13.12.2018 | University of Alberta

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: An energy-efficient way to stay warm: Sew high-tech heating patches to your clothes

Personal patches could reduce energy waste in buildings, Rutgers-led study says

What if, instead of turning up the thermostat, you could warm up with high-tech, flexible patches sewn into your clothes - while significantly reducing your...

Im Focus: Lethal combination: Drug cocktail turns off the juice to cancer cells

A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth – this was discovered by researchers from the University of Basel’s Biozentrum two years ago. In a follow-up study, recently published in “Cell Reports”, the scientists report that this drug cocktail induces cancer cell death by switching off their energy supply.

The widely used anti-diabetes drug metformin not only reduces blood sugar but also has an anti-cancer effect. However, the metformin dose commonly used in the...

Im Focus: New Foldable Drone Flies through Narrow Holes in Rescue Missions

A research team from the University of Zurich has developed a new drone that can retract its propeller arms in flight and make itself small to fit through narrow gaps and holes. This is particularly useful when searching for victims of natural disasters.

Inspecting a damaged building after an earthquake or during a fire is exactly the kind of job that human rescuers would like drones to do for them. A flying...

Im Focus: Topological material switched off and on for the first time

Key advance for future topological transistors

Over the last decade, there has been much excitement about the discovery, recognised by the Nobel Prize in Physics only two years ago, that there are two types...

Im Focus: Researchers develop method to transfer entire 2D circuits to any smooth surface

What if a sensor sensing a thing could be part of the thing itself? Rice University engineers believe they have a two-dimensional solution to do just that.

Rice engineers led by materials scientists Pulickel Ajayan and Jun Lou have developed a method to make atom-flat sensors that seamlessly integrate with devices...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

ICTM Conference 2019: Digitization emerges as an engineering trend for turbomachinery construction

12.12.2018 | Event News

New Plastics Economy Investor Forum - Meeting Point for Innovations

10.12.2018 | Event News

EGU 2019 meeting: Media registration now open

06.12.2018 | Event News

 
Latest News

Magic number colloidal clusters

13.12.2018 | Life Sciences

UNLV study unlocks clues to how planets form

13.12.2018 | Physics and Astronomy

Live from the ocean research vessel Atlantis

13.12.2018 | Earth Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>